Welcome to our dedicated page for Sintx Technologies news (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on Sintx Technologies stock.
SINTX Technologies, Inc. develops and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. Company news centers on its advanced ceramics platform, FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, OsseoSculpt™ biologic, and SiNERGY™ silicon nitride/PEEK composite materials for patient-specific implant applications.
Recurring updates also cover commercialization milestones, first-in-human use of SINTX implants, strategic supply and private-label agreements, patent activity in antipathogenic materials, capital actions, operating efficiencies, and management or board changes. The company’s updates frame its current focus around medical-device applications, orthopedic and spine markets, U.S.-based manufacturing, and partnerships that extend the use of silicon nitride biomaterials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
SINTX Technologies has completed renovations and equipment installation at its SINTX Armor facility in Salt Lake City, enhancing its capacity to manufacture high-performance ceramic armor products for personnel, aircraft, and vehicles. This facility spans 10,000 square feet and produces advanced materials like BoroShock and DuraShock, which offer lightweight, high-strength protection against projectiles. Following a strategic acquisition of B4C LLC, SINTX Armor anticipates a strong order book in 2023, aligning with a projected global ceramic armor market growth to USD $3.5 billion by 2027.